Search Results
Your search for all items matches 34717 pages
Showing 30251 - 30300Health and Economic Burden of Skin Cancer Substantial and Increasing, Highlighting the Value of Prevention Efforts
The average annual number of adults treated for skin cancer, both melanoma and nonmelanoma, in the United States increased from 3.4 million in 2002 to 2006 to 4.9 million in 2007 to 2011 (P < .001), according to a study published in the American Journal of Preventive Medicine. “During this...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
I Refuse to Capitulate to Cancer
Editor’s note: We regret to announce that Paul Kalanithi, MD, passed away on March 9, 2015. Dr. Kalanithi was Chief Resident in Neurological Surgery at Stanford University when he shared his story, reprinted here, with The ASCO Post just over 1 year ago, in March 2014. We extend our deepest...
Don’t Disregard Questions About Possible Symptoms of Colorectal Cancer Just Because the Patient Is ‘Too Young’
While colorectal cancer predominantly occurs in people over 50 years old, rates are increasing among younger patients. It is important for physicians not to ignore symptoms in patients who are young, “simply because they are young,” Jason A. Zell, DO, MPH, told The ASCO Post. Dr. Zell is the...
Colorectal Cancer Is Significantly Increasing Among Younger Adults and Being Diagnosed at Later Stages
A growing body of literature indicates that the incidence of colorectal cancer is rising among people under age 50, according to Jason A. Zell, DO, MPH. Dr. Zell is the corresponding author of one of the two recent studies finding significant increases in colorectal cancer among adults aged 20 to...
Shining a Spotlight on Epithelioid Hemangioendothelioma
In the winter of 2013, my son, Dmitriy, now 26, had a cough that wouldn’t go away. After several rounds of antibiotics failed to halt the persistent problem, a pulmonologist we consulted ordered a chest x-ray, which showed a large tumor lodged between Dmitriy’s lungs. Although the doctor said the...
A Surgeon Cuts to the Chase
BookmarkTitle: The Cost of Cutting: A Surgeon Reveals the Truth Behind a Multibillion-Dollar IndustryAuthor: Paul A. Ruggieri, MDPublisher: Berkley BooksPublication date: September 2014Price: $16.00; paperback, 320 pages The woman seated on the exam table was lean and fit and seemed perfectly at...
2015 Oncology Meetings
APRIL Melanoma and Cutaneous Malignancies MeetingApril 10-11 • New York, New York For more information: www.healio.com/meeting/hemonctodaymelanoma/home?promocode689-8045 Hematologic Malignancies: New Therapies and the Evolving Role of TransplantApril 10-11 • Chicago, Illinois For more information: ...
Technology’s Double-Edged Sword: One Woman’s Story
Bookmark Title: Pandora’s DNA: Tracing the Breast Cancer Genes Through History, Science, and One Family TreeAuthor: Lizzie StarkPublisher: Chicago Review PressPublication date: October 2014Price: $26.95; hardcover, 336 pages If we wish to learn more about cancer, we must concentrate on the cellular ...
The Ongoing Struggle Against Tobacco: Past Accomplishments, Future Steps
In 1913, 10 doctors and 5 laypersons in New York founded the American Cancer Society (ACS). At that time, a cancer diagnosis was almost always fatal and was rarely discussed in public. The Society’s original charter was to raise awareness about cancer, and although that mission has remained firm,...
Refining the ‘Right Patient, Right Drug’ Pairing in Cancer Care: RAS Profiling in Metastatic Colorectal Cancer
In an important post hoc analysis (reviewed in this issue of The ASCO Post), Van Cutsem and colleagues have further refined our knowledge of who are the “right” patients with metastatic colorectal cancer to receive treatment with cetuximab (Erbitux).1 This refinement was accomplished through the...
Adding Cetuximab to First-Line FOLFIRI Does Not Benefit Metastatic Colorectal Cancer Patients With RAS Mutations
The phase III CRYSTAL trial showed that the addition of cetuximab (Erbitux) to first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) significantly improved overall survival, progression-free survival, and objective response rates in patients with KRAS codon 12/13 (exon 2) wild-type...
ONS Lifetime Achievement Award
Deborah K. Mayer, PhD, RN, Director of Cancer Survivorship at the UNC Lineberger Comprehensive Cancer Center has been named the recipient of the 2015 Oncology Nursing Society Lifetime Achievement Award. The award recognizes her contributions as an oncology nurse researcher, mentor, and educator, as ...
American Association for Cancer Research Elects New Board of Directors, Nominating Committee Members
The members of the American Association for Cancer Research (AACR) have elected five members to serve on the AACR board of directors for the 2015–2018 term and four members to serve on the nominating committee for the 2015–2017 term. They will begin their terms at the AACR Annual Meeting 2015, to...
Why Just Having ‘Good’ Communication Skills Is Not Enough for Talking With Seriously Ill Patients
In the Institute of Medicine’s 2014 report Dying in America,1 the report’s authors found that while frequent clinician-patient conversations about end-of-life care, goals, and preferences are necessary to avoid unwanted treatment, most patients do not have those conversations with their physicians. ...
Nivolumab in Metastatic Squamous Non–Small Cell Lung Cancer After Platinum Therapy
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 4, 2015, the anti–programmed cell death protein 1 (PD-1) ...
FDA Approves Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis
The U.S. Food and Drug Administration (FDA) has approved Astellas’ New Drug Application for the use of isavuconazonium sulfate (Cresemba), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as...
The ASPIRE Trial of Carfilzomib in Relapsed Myeloma: A Major Step Forward
Currently in myeloma, there are at least five new agents that are either approved or in the late-stage of development with impending approval. Major questions in the field relate to how we, as clinicians, will use these new agents and where they will fit in the overall treatment schema. The phase...
Increased Progression-Free Survival With Addition of Carfilzomib to Lenalidomide/Dexamethasone in Relapsed Multiple Myeloma
In a planned interim analysis of the phase III ASPIRE trial reported in The New England Journal of Medicine, A. Keith Stewart, MB, ChB, of the Mayo Clinic, Scottsdale, Arizona, and colleagues found that the addition of the proteasome inhibitor carfilzomib (Kyprolis) to lenalidomide...
The Emerging Role of Radiation Therapy in Gastrointestinal Cancers
The use of radiation therapy in the treatment of gastrointestinal cancer has evolved over the past several decades, in a gradual, stepwise fashion. Since most gastrointestinal cancers are diagnosed at a locally advanced stage, coupled with the inherent sensitivity of most parts of the...
St. Jude Children’s Research Hospital Appoints Chair of Department of Radiation Oncology
St. Jude Children’s Research Hospital has named Thomas E. Merchant, DO, PhD, as Chair of the Department of Radiation Oncology. Dr. Merchant will hold the Baddia J. Rashid Endowed Chair in Radiation Oncology. “Dr. Merchant is a proven leader in pediatric radiotherapy and will be instrumental in...
Worker Safety When Handling Hazardous Drugs Is Focus of Statement by Oncology Societies
ASCO, the Hematology/Oncology Pharmacy Association (HOPA), and the Oncology Nursing Society (ONS) issued a joint position statement on improving the safety of health-care workers who handle dangerous drugs and other hazardous materials across various health-care settings. The statement offers seven ...
Researchers and Scientists Honored for Improving Cancer Prevention, Treatment, and Patient Care
The ASCO Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology community to enhancing cancer prevention, treatment, and patient care. Among this year’s awardees are an international leader in geriatric oncology...
Conquer Cancer Foundation Grants and Awards Program
Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF) is fueling cancer research and pursuing dramatic advances in the diagnosis, prevention, treatment, and cure of all kinds of cancer. At critical points for researchers, CCF is there with essential funding to power the next...
Stay Up to Date on New Patient Materials From Cancer.Net
Encourage your patients to use social media to stay up to date with the new resources available on Cancer.Net. It is easier than ever for patients to get the latest cancer information on their computer or mobile device. Subscribe to the Cancer.Net Blog at www.cancer.net/blog; connect to...
Researcher Spotlight: Conquering Cancer With Emily Ko, MD, MSCR
One of the best ways to prevent cancer is by finding new, better treatments for conditions that are considered risk factors. That is why Emily Ko, MD, MSCR, Assistant Professor of Obstetrics and Gynecology at the University of Pennsylvania School of Medicine, is investigating a new method for...
Current Progress Against Cancer and What Lies Ahead in the Next Decade
In January, ASCO released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer,1 which details research advances over the past decade that have led to longer survival and better quality of life for the more than half-a-million people diagnosed with cancer each...
Jim Hu, MD, Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College
Jim Hu, MD, has been appointed Director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and recruited as the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College. He assumed his new role on February 1. Dr. Hu is an expert in the use...
Global Oncology Launches Global Cancer Project Map With NCI
Nonprofit Global Oncology, Inc (GO) announced the launch of the Global Cancer Project Map, a novel online resource and virtual information exchange connecting the global cancer community. Developed by Global Oncology in collaboration with the National Cancer Institute (NCI) Center for Global...
Adjuvant Chemotherapy and Overall Survival in Muscle-Invasive Bladder Cancer: Still Climbing the Mountain
Muscle-invasive bladder cancer can be a lethal disease despite curative intent local therapy, with 5-year survival that can be as low as 30% based on the extent of T status and/or lymph node involvement. The use of neoadjuvant chemotherapy with MVAC (methotrexate, vinblastine, doxorubicin, and...
No Overall Survival Difference for Immediate vs Deferred Chemotherapy After Radical Cystectomy in Muscle-Invasive Bladder Cancer
In the European Organisation for Research and Treatment of Cancer (EORTC) 30994 trial, a phase III intergroup study reported in The Lancet Oncology,1 Cora N. Sternberg, MD, FACP, Chief of Medical Oncology at San Camillo and Forlanini Hospitals, Rome, and colleagues found no overall survival...
NCCN Honors Joseph V. Simone, MD, FASCO, and John A. Gentile, Jr, at Group’s 20th Annual Conference
At the National Comprehensive Cancer Network (NCCN) 20th Annual Conference held last month in Hollywood, Florida, NCCN honored Joseph V. Simone, MD, FASCO, and John (Jack) A. Gentile, Jr, with the NCCN Board of Producers Award. Dr. Simone is President of Simone Consulting Company, which advises...
Michael H. Levy, MD, PhD, Receives Lifetime Achievement Award
Michael H. Levy, MD, PhD, Director of the Pain and Palliative Care Program at Fox Chase Cancer Center, and one of the founding leaders of the American hospice and palliative care movement, has received the Lifetime Achievement Award from the American Academy of Hospice and Palliative Medicine...
Biosimilar Filgrastim-sndz in Filgrastim Indications
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 6, 2015, the granulocyte colony-stimulating factor...
EMPEROR Science Award Program
Stand Up To Cancer (SU2C) and PBS LearningMedia announced The EMPEROR Science Award Program. This initiative will encourage students from disadvantaged high schools to pursue careers in science, with a particular emphasis on cancer research, through a year of mentorship with a scientist from a...
Breast Cancer Management in Review
Anyone who has attended the major oncology meetings knows that research from clinical trials in breast cancer often dominates the stage, with countless abstracts featuring new and updated results. To help the readers of The ASCO Post stay up to date with the latest discoveries and findings...
James P. Allison, PhD, Wins 2015 Paul Ehrlich and Ludwig Darmstaedter Prize
James P. Allison, PhD, Chair of Immunology at The University of Texas MD Anderson Cancer Center, has received the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize in recognition of his work in the field of immunotherapy. “In immunotherapy, it’s not the tumor but the immune system that is targeted....
FDA Approves Nivolumab to Treat Metastatic Squamous NSCLC
The U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor nivolumab (Opdivo) for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. Nivolumab is a monoclonal antibody that binds to the...
FDA Approves First Biosimilar Product Filgrastim-Sndz
The U.S. Food and Drug Administration (FDA) has approved filgrastim-sndz (Zarxio), the first biosimilar product approved in the United States. A biosimilar product is a biologic product that is approved based on a showing that it is highly similar to an already-approved biologic. The biosimilar...
Results of RTOG 0617 Reconsidered
Radiation Therapy Oncology Group (RTOG) 0617 was a study initially designed to address an important issue in radiation oncology regarding the treatment of stage III non–small cell lung cancer (NSCLC): Are outcomes improved with high-dose as opposed to standard-dose thoracic radiation therapy? The...
Calculating H-Score
Immunohistochemistry results can be further evaluated by a semiquantitative approach used to assign an H-score (or “histo” score) to tumor samples.1,2 First, membrane staining intensity (0, 1+, 2+, or 3+) is determined for each cell in a fixed field. The H-score may simply be based on a predominant ...
No Benefit of High- vs Standard-Dose Radiotherapy or Addition of Cetuximab to Chemoradiation in Stage IIIA/IIIB NSCLC
As reported in The Lancet Oncology by Jeffrey D. Bradley, MD, of Washington University, and colleagues, the phase III Radiation Therapy Oncology Group 0617 trial showed no survival benefit of high- vs standard-dose radiotherapy or addition of cetuximab (Erbitux) to concurrent...
New Tobacco Atlas Details Scale and Harm of the Tobacco Epidemic
The Tobacco Atlas, fifth edition, its companion mobile app, and website TobaccoAtlas.org, were released by the American Cancer Society and World Lung Foundation at the 16th World Conference on Tobacco or Health held March 17–21, 2015 in Abu Dhabi, United Arab Emirates. The Atlas details the scale...
Dinutuximab in Pediatric High-Risk Neuroblastoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 10, 2015, the chimeric monoclonal antibody dinutuximab...
State Oncology Societies Join ASCO’s Call on Congress to Replace SGR Formula
In a show of solidarity, state oncology societies from across the United States joined ASCO in its call on Congress to repeal Medicare’s Sustainable Growth Rate (SGR) formula before the current payment patch expires. In a letter to U.S. House and Senate leadership, 48 signatories, representing tens ...
Expert Point of View: Eric J. Small, MD
Eric J. Small, MD, of the University of California at San Francisco, discussed what he thought went wrong for cabozantinib (Cometriq) in the COMET-1 trial, yet another example of a phase III trial that failed to deliver on the promise of phase II results. “Although this was a negative study,...
Cabozantinib Fails to Improve Survival in Metastatic Castration-Resistant Prostate Cancer
Final results of the phase III, randomized double-blind, controlled COMET-1 trial were disappointing. Although the oral tyrosine kinase inhibitor cabozantinib (Cometriq) improved several secondary endpoints compared with prednisone, including bone scan response and progression-free survival, the...
NCCN Publishes New Guidelines for Smoking Cessation
Tobacco-related diseases are the most preventable cause of death worldwide. According to the American Cancer Society, in 2015, nearly 171,000 of the estimated 589,430 cancer deaths in the United States—more than 25%—will be caused by tobacco smoking. Smoking cessation leads to improvement in cancer ...
Expert Point of View: Howard Scher, MD
AR-V7 is only one of the many prostate cancer predictive biomarker candidates currently under investigation,” said Howard Scher, MD, Chief of the Genitourinary Service at Memorial Sloan Kettering Cancer Center in New York. While preliminary data are promising, further development of AR-V7 will...
Evidence Mounts for Clinical Utility of AR-V7 in Treatment Selection for Advanced Prostate Cancer
The search is on in prostate cancer to identify predictive and prognostic biologic and genomic markers that go beyond traditional ones. Several groups are working in this area. One marker that has received much attention is a splice abnormality in the androgen receptor (AR) called AR-V7. Two...
